1. Home
  2. GSHD vs PHVS Comparison

GSHD vs PHVS Comparison

Compare GSHD & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Goosehead Insurance Inc.

GSHD

Goosehead Insurance Inc.

HOLD

Current Price

$46.52

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$35.06

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSHD
PHVS
Founded
2003
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.4B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
GSHD
PHVS
Price
$46.52
$35.06
Analyst Decision
Buy
Buy
Analyst Count
12
11
Target Price
$72.50
$41.82
AVG Volume (30 Days)
287.0K
1.0M
Earning Date
04-22-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.04
N/A
Revenue
$365,304,000.00
N/A
Revenue This Year
$16.40
N/A
Revenue Next Year
$18.53
N/A
P/E Ratio
$49.71
N/A
Revenue Growth
16.15
N/A
52 Week Low
$33.68
$20.65
52 Week High
$79.85
$43.25

Technical Indicators

Market Signals
Indicator
GSHD
PHVS
Relative Strength Index (RSI) 26.74 45.46
Support Level $40.71 $32.77
Resistance Level $56.00 $36.80
Average True Range (ATR) 3.63 2.09
MACD -1.76 -0.23
Stochastic Oscillator 2.86 16.07

Price Performance

Historical Comparison
GSHD
PHVS

About GSHD Goosehead Insurance Inc.

Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: